Classify every gene variant. Match every patient to the right drug.
Most gene variants in cancer and rare disease are Variants of Uncertain Significance (VUS), leaving targeted therapies out of reach for patients who could benefit. And even well-established disease-causing variants need deeper functional understanding to drive the patient stratification, biomarker integration, and label expansion that modern precision medicine demands.
Using geneSlice, our proprietary gene editing platform, we build high-throughput functional assays that resolve gene variants into actionable classifications — so drug developers can guide patient selection, design better-tailored trials, expand label eligibility, and accelerate precision medicine programmes.
For most clinically actionable genes, only a fraction of patient variants are classified.
The majority — particularly missense variants — remain functionally uncharacterised, leaving trial design and treatment decisions without the variant-level data they need.
Our approach
We engineer cell models for each variant of interest and run them through high-throughput functional assays. The output: variant-level drug sensitivity data at scale, ready to inform trial design, patient stratification, and label-expansion programmes.
Two pathways, one platform
Every project begins with a consultation. From there, projects run on one of two pathways — a productised variant-library workflow, or a bespoke design when the standard shape isn't the right fit.
Variant library workflow
Consultation
Scope the gene, variant library, and readout.
2–4 weeksCell line development
geneSlice-powered cell line build.
~6 monthsVariant library & screening
Library construction, delivery, and functional assays.
~6 monthsData delivery
Functional scores, resistance maps, annotated databases.
deliverableBespoke workflow
Consultation
Scientific question and assay architecture.
2–4 weeksBespoke assay design
Custom cell-line build and tailored readouts.
scopedExecution
Functional assays, arrayed screens, and bioinformatics.
scopedData delivery
As agreed.
deliverableTotal timeline: typically 6–12 months for variant library projects; bespoke projects scoped per project. See Technology for the full process.
Functional genomics, end to end
Oncology
Variant classification for patient stratification, label expansion, and resistance anticipation.
Rare Genetic Diseases
Functional answers for rare disease, neurodegenerative, cardiovascular, and other genetically defined disorders.
Compound–Target Assay
Residue-level resistance and sensitivity maps for compound–target programmes.
Custom Services
Bespoke assays for projects outside the standard shape.
CRISPR Therapeutics
Safety and QC support for CRISPR-based therapy developers.
Active programmes with leading pharmaceutical companies, biotech innovators, and academic partners.
Development partner: TIDE Genetics.